Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, highlights the safety and efficacy of carfilzomib, lenalidomide and dexamethasone in myeloma patients post-autologous stem cell transplantation (autoSCT). Dr Schjesvold first highlights the patient selection process in this Phase II trial, and then goes on to discuss the efficacy and main outcomes, as well as the importance of following up on progression-free survival data in the future. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть